Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hypogonadism × Tamoxifen × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 100 Carcinoma, Intraductal, Noninfiltrating 12 Breast Carcinoma In Situ 10 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Breast Neoplasms, Male 6 Neoplasms 5 Glioblastoma 5 Central Nervous System Neoplasms 5 Prostatic Neoplasms 4 Gliosarcoma 4 Inflammatory Breast Neoplasms 3 Glioma 3 Brain Neoplasms 3 Astrocytoma 3 Urinary Bladder Neoplasms 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Glioma, Subependymal 2 Fallopian Tube Neoplasms 2 Ependymoma 2 Breast Cancer Female 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Sarcoma 1 Risk Reduction Behavior 1

Interventions

Testosterone 2 testosterone undecanoate 1 Tamoxifen 1 Gels 1 Drug Evaluation 1 Clomiphene 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07535905 2026-04-17

REVIVE

University Health Network, Toronto

Phase 2 Not yet recruiting

Hypogonadism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡